Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.59 USD | -3.45% | -9.81% | +91.24% |
Business Summary
Number of employees: 385
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines for Cellular Metabolism
100.0
%
| 14 | 100.0 % | 27 | 100.0 % | +88.36% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 14 | 100.0 % | 27 | 100.0 % | +88.36% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 22-09-25 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
Sarah Gheuens
CTO | Chief Tech/Sci/R&D Officer | 45 | 19-11-30 |
Clive Patience
CTO | Chief Tech/Sci/R&D Officer | 60 | 17-05-31 |
David Schenkein
BRD | Director/Board Member | 66 | 09-07-31 |
Investor Relations Contact | - | - | |
Charlie Newman
PRN | Corporate Officer/Principal | - | 21-12-31 |
Ellen Lopresti
HRO | Human Resources Officer | - | 16-12-31 |
T. Washburn
AUD | Comptroller/Controller/Auditor | 43 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 23-05-31 |
Director/Board Member | 64 | 14-12-08 | |
May Kin Ho
BRD | Director/Board Member | 71 | 15-06-22 |
David Schenkein
BRD | Director/Board Member | 66 | 09-07-31 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
David Scadden
BRD | Director/Board Member | 71 | 17-05-26 |
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cynthia Smith
BRD | Director/Board Member | 55 | 22-08-10 |
Rahul Ballal
BRD | Director/Board Member | 46 | 22-08-10 |
Catherine Owen
BRD | Director/Board Member | 53 | 23-06-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 72,989,377 | 55,931,414 ( 76.63 %) | 16,216,411 ( 22.22 %) | 76.63 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.24% | 2.42B | |
+16.42% | 122B | |
+19.02% | 113B | |
+3.06% | 22.66B | |
-11.63% | 16.68B | |
-16.33% | 16.61B | |
-39.57% | 16.92B | |
+2.68% | 13.62B | |
+21.16% | 11.04B | |
+108.78% | 10.43B |
- Stock Market
- Equities
- AGIO Stock
- Company Agios Pharmaceuticals, Inc.